ULACNet Virtual Annual Meeting 2022
The US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network (ULACNet) focuses on developing evidence to improve and optimize approaches for prevention of human papillomavirus (HPV)-related cancers in people living with human immunodeficiency virus (HIV) infection.
This international collaborative research network brings together institutions in the United States and counterparts in low- and middle-income countries (LMICs) in the Latin American and Caribbean (LAC) region. Funded in Fall 2019 via a U54 Partnership Centers Cooperative Agreement mechanism, ULACNet comprises of three Partnership Centers each collaboratively conducting a multidisciplinary Clinical Trials Program supported via an infrastructure of an Administrative and Coordinating Core, a Data Management and Statistical Core, and a Central Laboratory Core. ULACNet investigators collaborate with the NCI to design and conduct clinical trials on three key scientific areas, immunoprevention, screening and triage, and precancer therapeutics, together spanning the continuum of prevention intervention opportunities for HPV-related cancers among people living with HIV.
The 2022 Annual Meeting will be held virtually on Wednesday, November 30, 2022 and bring together investigators, clinicians, site coordinators, and program staff from partner institutions in the US, Mexico, Puerto Rico, Brazil, Peru, the Dominican Republic and Haiti. The meeting will include a scientific session with invited speakers and presentations and discussions on current and future clinical trials in the network.
For more information on ULACNet, please contact ULACNet@mail.nih.gov or Vikrant Sahasrabuddhe, M.B.B.S., Dr.P.H. in the NCI Division of Cancer Prevention.